A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

NCT06959537 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Axatilimab (SNDX-6352)
DRUG: Retifanlimab

Sponsor

M.D. Anderson Cancer Center